Molecular Formula | C15H18N4O4S |
Molar Mass | 350.39 |
Melting Point | 265-271°C (dec.) |
Specific Rotation(α) | D20 -32.9° (c = 0.5) |
Solubility | H2O : 5 mg/mL (ultrasonic) mother liquor preservation: sub-package and freeze storage to avoid repeated freezing and thawing;-20 ℃,1 month;-80 ℃,6 months (after dilution, the solution temperature is low and storage may precipitate, as far as possible) Cell experiment: dissolve with DMSO first: dilute with culture medium then, and the dilution process is recommended to be carried out in stages to avoid too fast concentration change leading to compound precipitation. If the compound is precipitated during the dilution process, it can be redissolved by ultrasound. During dilution, ensure that the final concentration of DMSO in the working fluid should be below 0.1% as far as possible, and the maximum should not exceed 0.5%, and set up a DMSO control group with corresponding concentration. Animal experiment: Dissolve with DMSO first: dilute with water or normal saline, etc. The dilution process is recommended to be carried out in sections to avoid excessive concentration changes leading t |
Appearance | powder |
Color | white to beige |
Storage Condition | -20°C |
Refractive Index | 1.651 |
Use | For the total synthesis of the class of antibacterial drugs |
WGK Germany | 3 |
Reference Show more | 1: Nakagawa Y, Suzuki K, Hirose T, Chou T, Fujisawa S, Kida M, Usuki K, Ishida Y, Taniguchi S, Kouzai Y, Tomoyasu S, Miyazaki K, Higashihara M, Ando K, Aoki S, Arai A, Akiyama N, Hatake K, Okamoto S, Dan K, Ohyashiki K, Urabe A. Erratum to: Clinical efficacy and safety of biapenem for febrile neutropenia in patients with underlying hematopoietic diseases: a multi-institutional study. J Infect Chemother. 2010 Dec 8. [Epub ahead of print] PubMed PMID: 21140280. 2: Jia B, Lu P, Huang W, Li C, Huang A, Zhou X, Zhang W, Wu G, Zhang G. A multicenter, randomized controlled clinical study on biapenem and imipenem/cilastatin injection in the treatment of respiratory and urinary tract infections. Chemotherapy. 2010;56(4):285-90. Epub 2010 Aug 11. PubMed PMID: 20714145. 3: Nakagawa Y, Suzuki K, Hirose T, Chou T, Fujisawa S, Kida M, Usuki K, Ishida Y, Taniguchi S, Kouzai Y, Tomoyasu S, Miyazaki K, Higashihara M, Ando K, Aoki S, Arai A, Akiyama N, Hatake K, Okamoto S, Dan K, Ohyashiki K, Urabe A. Clinical efficacy and safety of biapenem for febrile neutropenia in patients with underlying hematopoietic diseases: a multi-institutional study. J Infect Chemother. 2010 Jul 3. [Epub ahead of print] PubMed PMID: 20602137. 4: Kameda K, Ikawa K, Ikeda K, Morikawa N, Nakashima A, Ohge H, Sueda T. HPLC method for measuring meropenem and biapenem concentrations in human peritoneal fluid and bile: application to comparative pharmacokinetic investigations. J Chromatogr Sci. 2010 May-Jun;48(5):406-11. PubMed PMID: 205 |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.854 ml | 14.27 ml | 28.54 ml |
5 mM | 0.571 ml | 2.854 ml | 5.708 ml |
10 mM | 0.285 ml | 1.427 ml | 2.854 ml |
5 mM | 0.057 ml | 0.285 ml | 0.571 ml |